Evolving Strategies of Care in Pulmonary Arterial Hypertension
Pulmonary Disease
Curriculum:
Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Evolving Strategies of Care in Pulmonary Arterial Hypertension: Integrating the Data into Practice
Credits:
1 AMA PRA Category 1 Credit(s) ™ 1 AANP Contact Hours 0.75 Pharmacology
1 AMA PRA Category 1 Credit(s) ™ 1 AANP Contact Hours 0.75 Pharmacology
Launch Date:
September 06, 2018
September 06, 2018
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Primary Care Physicians; Nurse Practitioners (NPs); Physician Assistants (PAs); and other clinicians.
Relevant Terms:
Pulmonary arterial hypertension; pulmonary hypertension; dsypnea
Franck Rahaghi, MD, MHS, FCCP
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL
Bio
Dr. Franck Rahaghi graduated from the University of California San Diego Magna Cum Laude with a degree in biomedical engineering. He subsequently attended the University of California San Francisco where he obtained his doctorate in medicine. He also concurrently attended University of California Berkeley to obtain a degree in public health and health administration. Dr. Rahaghi completed his internship at the University of Minnesota and in his medical residency at the University of Illinois in Chicago. He completed his pulmonary and critical care fellowship at the Weil-Cornell campus of New York Presbyterian Hospital. He is the chairman of the department of pulmonary medicine at the Cleveland Clinic Florida. Dr. Rahaghi was named the Scholar physician of the year at the Cleveland Clinic Florida in 2012. He holds the positions of Director of Advance Lung Disease Program/ Pulmonary Hypertension Clinic, and Director of the Alpha-1 Foundation Clinical Resources Center.| 1. | Review the risk factors and classification of pulmonary hypertension (PH) | 2. | Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC) |
| 3. | Review current and emerging treatments for patients with PAH | 4. | Describe how to monitor patients with PAH for disease progression |
| 1. | Review the risk factors and classification of pulmonary hypertension (PH) |
| 2. | Discuss the appropriate diagnostic strategy for pulmonary arterial hypertension (PAH), including the roles of echocardiography, ventilation/perfusion (V/Q) scanning, and right heart catheterization (RHC) |
| 3. | Review current and emerging treatments for patients with PAH |
| 4. | Describe how to monitor patients with PAH for disease progression |
Planning Committee
Alexander Duarte, MD
Professor, Division of Pulmonary Critical Care & Sleep Medicine
Department of Internal Medicine
University of Texas Medical Branch
Galveston, TX
Arunabh Talwar, MD, FCCP
Director, Pulmonary Hypertension and Advanced Lung Disease Program
North Shore University Hospital, Manhasset, New York
Professor of Medicine
Donald and Barbara Zucker School of Medicine Hofstra/ Northwell Hofstra University
Hempstead, NY
Gregg Sherman, MD
Chief Medical Officer/Course Director
National Association for Continuing Education
Plantation, FL
Sandy Bihlmeyer, M.Ed.
National Association for Continuing Education
Plantation, FL
Sheila Lucas, CWEP
National Association for Continuing Education
Plantation, FL
Joshua Kilbridge, President
Kilbridge Associates
San Francisco, CA
Kilbridge Associates
San Francisco, CA
PROGRAM OVERVIEW:
Pulmonary arterial hypertension (PAH) is a subgroup of pulmonary hypertension (PH) and a chronic, progressive condition characterized by abnormally high pressure in the pulmonary vasculature. PAH has previously been considered a rare disease, but evidence suggests a prevalence of about 15-50 cases per million. In the United States, about 1,000 new cases of PAH are diagnosed each year.
The prognosis of PAH has improved with the availability of newer therapies, but outcomes are dependent on early diagnosis and treatment. This activity utilizes segments of a presentation by the faculty recorded at the Emerging Challenges in Primary Care Live Virtual Symposium: 2018, to reinforce teaching points made during this program. This program will address recognizing the signs and symptoms of PAH, performing an appropriate diagnostic evaluation, current treatment paradigm, managing adverse medication events and when to refer to tertiary PH centers.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
Faculty
Franck Rahaghi, MD, MHS, FCCP serves as a consultant, speaker, and researcher for Actelion, Bayer, and Gilead. He also serves as a consultant and speaker for United Therapeutic.
Planning Committee
Alexander Duarte, MD has no financial relationships to disclose.
Arunabh Talwar, MD, FCCP serves as a speaker for Boehringer Ingelheim. Dr. Talwar also serves on the advisory board for Genentech.
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.
Sandy Bihlmeyer, M.Ed., has no real or apparent conflicts of interest to report.
Sheila Lucas, CWEP, has no real or apparent conflicts of interest to report.
Harvey Parker, PhD, has no real or apparent conflicts of interest to report.
Joshua Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
DISCLAIMER
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
ACCREDITATION STATEMENT:
The National Association for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
For CME questions, please contact: NACE at info@naceonline.com
Contact this CME provider for privacy and confidentiality policy statement information at:
https://www.naceonline.com/privacy_policy.php
CREDIT DESIGNATION STATEMENT:
NACE designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hours of continuing education (which includes 0.75 hours of pharmacology).
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
ACKNOWLEDGEMENT:
This activity is sponsored by National Association for Continuing Education.
This educational activity is supported by an educational grant from Actelion Pharmaceuticals US, Inc.
If you have any questions regarding this activity, send an email to info@naceonline.com.
Copyright © 2018 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above. |
© 2007-2024 HealthCourse, Inc. All rights reserved.
